ロード中...
Comments on Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated wit...
保存先:
| 出版年: | Toxins (Basel) |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7076756/ https://ncbi.nlm.nih.gov/pubmed/31979238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/toxins12020071 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|